KEVIN OBI: Open Payments
NPI 1679062640 · UNION, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,251 in 249 payments from 13 companies in 2025. Trend: 2023 $1,611 · 2024 $2,966 · 2025 $5,251
Food & beverage: $5,251
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 49 | $1,224 |
| E.R. Squibb & Sons, L.L.C. | 55 | $1,156 |
| Janssen Pharmaceuticals, Inc | 25 | $611 |
| Neurocrine BioSciences, Inc. | 18 | $461 |
| Alkermes, Inc. | 24 | $430 |
| ABBVIE INC. | 26 | $367 |
| Vanda Pharmaceuticals Inc. | 10 | $352 |
| Braeburn Inc. | 14 | $208 |
| Otsuka America Pharmaceutical, Inc. | 10 | $167 |
| Teva Pharmaceuticals USA, Inc. | 10 | $149 |
Products named: CAPLYTA, COBENFY, INGREZZA, ARISTADA, INVEGA SUSTENNA, VRAYLAR, SPRAVATO, FANAPT.
Industry payments across NJ — which companies pay providers there.
